Racemetyrosine

Unassigned

New Medicines

Advanced metastatic pancreatic cancer - third-line monotherapy

Information

New molecular entity
TYME
TYME

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

Antimetabolite, involves dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells
Advanced pancreatic cancer is difficult to treat with the lowest survival rates among all cancers. Across all patients with pancreatic cancer, relative 5-year survival is 6% and is less than 2% for those with advanced disease [1].
Advanced metastatic pancreatic cancer - third-line monotherapy
Oral